FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900893526> ?p ?o ?g. }

• W2900893526 endingPage "633" @default.
• W2900893526 startingPage "631" @default.
• W2900893526 abstract "The optimal duration of anticoagulation after an unprovoked venous thromboembolism (VTE) is unknown. Three tools that predict recurrence for patients with unprovoked VTE exist: the HERDOO2 [Hyperpigmentation, oEdema or Redness in either leg; D-dimer level ≥250 μg/l; Obesity (body mass index ≥30); or Older age (≥65 years)] score, the Vienna prediction model and the DASH score (Rodger et al, 2008; Eichinger et al, 2010; Tosetto et al, 2012). The DASH score comprises the D-dimer 1 month after stopping anticoagulation (score: +2 if positive), age (+1 if ≤50 years), sex (+1 if male) and use of hormonal therapy (−2) (Tosetto et al, 2012). Annual recurrence rates are 3·1% [95% confidence interval (CI) 2·3–3·9] for a score of ≤1, 6·4% (95% CI 4·8–7·9) for ≥2 and 12·3% (95% CI 9·9–14·7) for ≥3 (Tosetto et al, 2012). At our institution, a DASH of ≤1 has been used to discourage long-term anticoagulation in patients with unprovoked VTE where the decision is in equipoise. This study aimed to evaluate the VTE recurrence rate of patients with low DASH scores (≤1) treated at our institution. Medical charts of patients seen in the thrombophilia clinic between 1 January 2013 and 31 December 2016 with a first episode of unprovoked (as defined by Tosetto et al, 2012) or hormone-provoked VTE [proximal deep vein thrombosis (DVT) or pulmonary embolism] were reviewed. The censor date was VTE recurrence, death or 12 April 2018 (whichever occurred first). D-dimer testing was performed 1 month after stopping anticoagulation. Patients were tested for antithrombin deficiency (but not routinely other heritable thrombophilias) and antiphospholipid antibodies as these can influence treatment. The primary outcome was recurrent VTE, which was diagnosed when there was objective radiological evidence of a new VTE. Distal DVT was excluded. Statistical analysis was performed using Microsoft Excel 2010 (Microsoft, Redmond, WA, USA); 95% confidence intervals (CIs) were calculated using the exact binomial method. This project was registered with the hospital audit department. Unprovoked VTE was identified in 452 patients; 5 were lost to all follow-up, 145 continued anticoagulation without a DASH, 27 stopped anticoagulation after the initial treatment period without a DASH and 271 had a DASH calculated, whilst 4 patients had a VTE recurrence having stopped anticoagulation to determine a DASH score and subsequently continued anticoagulation long-term. Of the 271 patients with a DASH score, 145 had a score ≤1 and stayed off anticoagulation, 6 had a DASH ≤1 and resumed anticoagulation, 88 had a DASH ≥2 and resumed anticoagulation and 32 had a DASH ≥2 and stayed off anticoagulation (individual treatment was decided on patient factors, such as preference and perceived bleeding risk). For the 145 patients with a DASH score ≤1 that stayed off anticoagulation there were no recurrences during the initial anticoagulant treatment period (characteristics in Table 1); mean age was 62 years and 52·4% were male. No group of patients with a DASH ≤1 had a recurrence rate less than 5/100 patient years and of the recurrences, 12 were male and 10 female (Table 2). Expert consensus is that if VTE recurrence rate at 1 year is less than 5% or 15% at 5 years then this is acceptably low to withhold anticoagulation (Kearon et al, 2010). Our findings suggest rates above this; however, this threshold is debatable with low dose direct oral anti-coagulants which have a favourable bleeding profile (Agnelli et al, 2013 & Weitz et al, 2017). Patients that had a DASH score ≤1 represented a clinically low risk group (patients that continued anticoagulation without a DASH score had diverse risk factors for recurrence; data not shown), which makes the recurrence rate surprisingly high. In a recent validation of the DASH score, the recurrence rate for patients aged >65 years was >5% annually even with low DASH scores and therefore the relatively old population in our study (average age for DASH ≤1: 62 years) may have affected recurrence rates; however when patients aged >50 and <65 years were examined in our study, recurrence rates were >5/100 patient years (Tosetto et al, 2017). Tosetto et al (2017) also observed that a DASH score of 1 had an annual recurrence rate of 5·3% (95% CI 5·1–5·4) although the annual rates were significantly lower [3·9% (95% CI 3·6–4·2) and 0·5% (95% CI 0·4–0·6)] for scores of 0 and ≤−1 respectively, but our findings did not replicate this for the sub-group with a score ≤0. It is known that males have higher recurrence rates (the HERDOO2 score does not allow them to stop anticoagulation) but even when they are excluded (DASH ≤0; Table 2) the recurrence rate was more than 5/100 patient years (Rodger et al, 2008). The HERDOO2 score has recently been validated and included patients with ‘weakly provoked’ VTE (aside from hormone therapy), which is a lower risk population in terms of VTE recurrence compared to predominantly unprovoked patients in our study (Rodger et al, 2017). Our study has several limitations. It is an audit of the DASH score at our centre rather than a prospective validation study and outcomes were not adjudicated. The patient's medical charts were examined at our hospital but no information was available on events reported to other centres or on causes of death. Patients were treated with anticoagulation for various periods prior to a DASH score calculation. There may have been variation in treatment decisions between the clinicians and heterogeneous treatment groups subject to selection bias (e.g. long-term anticoagulation versus patients that had DASH score calculated). Patient data, e.g. weight, was not systematically collected. Finally, our study included smaller numbers of patients and sub-groups in comparison to other DASH studies (Tosetto et al, 2012, 2017). Irrespective of these limitations, the study represents routine use of the DASH score and the dilemmas with such patients. In summary, we could not find patients with a low DASH score with a VTE recurrence rate below which anticoagulation could be withheld. It is unclear why the DASH score did not perform as expected in our clinic. Future work to validate and refine VTE recurrence tools is justified or, alternatively, identify safer anticoagulants so that treatment decisions are less finely balanced (Bickmann et al, 2017). SM – performed data analysis and wrote the manuscript. RC – collected data and approved the final draft. AX – collected data and approved the final draft. MB – provided conceptual input and approved the final draft. KS – provided conceptual input, edited the final draft and designed the study. WT – collected data, wrote the manuscript and designed the study. We thank our colleague Dr Trevor Baglin for the clinical care of these patients and a useful discussion regarding the findings. SM – nothing to declare. RC – nothing to declare. AH – nothing to declare. MB – speaking honorarium from Alexion, advisory board for Viforpharma, educational meeting organized by Novartis, administrative support from cosmopharma, honorarium from Haemosonic. KS – educational support from Actelion, Bayer, GlaxoSmithKline, and Merck Sharp & Dohme to attend conferences/scientific meetings. WT – speaking honorarium from Pfizer, fees for advisory boards from Ablynx & Daiichi Sankyo and has had support to attend educational meetings from BioMarin, Novo Nordisk, Sobi, Octapharma and LFB Biopharmaceuticals." @default.
• W2900893526 created "2018-11-29" @default.
• W2900893526 creator A5031631312 @default.
• W2900893526 creator A5058546945 @default.
• W2900893526 creator A5064196342 @default.
• W2900893526 creator A5074959490 @default.
• W2900893526 creator A5079755719 @default.
• W2900893526 creator A5086382008 @default.
• W2900893526 creator A5086905861 @default.
• W2900893526 date "2018-11-15" @default.
• W2900893526 modified "2023-09-27" @default.
• W2900893526 title "Utility of the <scp>DASH</scp> score after unprovoked venous thromboembolism; a single centre study" @default.
• W2900893526 cites W1524501969 @default.
• W2900893526 cites W1573523596 @default.
• W2900893526 cites W2003601153 @default.
• W2900893526 cites W2113530759 @default.
• W2900893526 cites W2139785591 @default.
• W2900893526 cites W2595086780 @default.
• W2900893526 cites W2595581694 @default.
• W2900893526 cites W2736925049 @default.
• W2900893526 cites W2740950031 @default.
• W2900893526 cites W2989714602 @default.
• W2900893526 doi "https://doi.org/10.1111/bjh.15597" @default.
• W2900893526 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30443905" @default.
• W2900893526 hasPublicationYear "2018" @default.
• W2900893526 type Work @default.
• W2900893526 sameAs 2900893526 @default.
• W2900893526 citedByCount "7" @default.
• W2900893526 countsByYear W29008935262019 @default.
• W2900893526 countsByYear W29008935262020 @default.
• W2900893526 countsByYear W29008935262021 @default.
• W2900893526 countsByYear W29008935262023 @default.
• W2900893526 crossrefType "journal-article" @default.
• W2900893526 hasAuthorship W2900893526A5031631312 @default.
• W2900893526 hasAuthorship W2900893526A5058546945 @default.
• W2900893526 hasAuthorship W2900893526A5064196342 @default.
• W2900893526 hasAuthorship W2900893526A5074959490 @default.
• W2900893526 hasAuthorship W2900893526A5079755719 @default.
• W2900893526 hasAuthorship W2900893526A5086382008 @default.
• W2900893526 hasAuthorship W2900893526A5086905861 @default.
• W2900893526 hasBestOaLocation W29008935261 @default.
• W2900893526 hasConcept C111919701 @default.
• W2900893526 hasConcept C126322002 @default.
• W2900893526 hasConcept C143998085 @default.
• W2900893526 hasConcept C177713679 @default.
• W2900893526 hasConcept C2776090536 @default.
• W2900893526 hasConcept C2780868729 @default.
• W2900893526 hasConcept C2991741193 @default.
• W2900893526 hasConcept C41008148 @default.
• W2900893526 hasConcept C71924100 @default.
• W2900893526 hasConceptScore W2900893526C111919701 @default.
• W2900893526 hasConceptScore W2900893526C126322002 @default.
• W2900893526 hasConceptScore W2900893526C143998085 @default.
• W2900893526 hasConceptScore W2900893526C177713679 @default.
• W2900893526 hasConceptScore W2900893526C2776090536 @default.
• W2900893526 hasConceptScore W2900893526C2780868729 @default.
• W2900893526 hasConceptScore W2900893526C2991741193 @default.
• W2900893526 hasConceptScore W2900893526C41008148 @default.
• W2900893526 hasConceptScore W2900893526C71924100 @default.
• W2900893526 hasIssue "3" @default.
• W2900893526 hasLocation W29008935261 @default.
• W2900893526 hasLocation W29008935262 @default.
• W2900893526 hasOpenAccess W2900893526 @default.
• W2900893526 hasPrimaryLocation W29008935261 @default.
• W2900893526 hasRelatedWork W2145532404 @default.
• W2900893526 hasRelatedWork W2155855469 @default.
• W2900893526 hasRelatedWork W2331409909 @default.
• W2900893526 hasRelatedWork W2595840590 @default.
• W2900893526 hasRelatedWork W2760183634 @default.
• W2900893526 hasRelatedWork W2765659125 @default.
• W2900893526 hasRelatedWork W2982059048 @default.
• W2900893526 hasRelatedWork W3000568411 @default.
• W2900893526 hasRelatedWork W4238477798 @default.
• W2900893526 hasRelatedWork W4238549103 @default.
• W2900893526 hasVolume "185" @default.
• W2900893526 isParatext "false" @default.
• W2900893526 isRetracted "false" @default.
• W2900893526 magId "2900893526" @default.
• W2900893526 workType "article" @default.